newest glp 1 drug Eli Lilly to seek approval of new GLP-1 weight-loss this year Understanding GLP-1 pills: A new

Liraglutide was shown to prevent synapse loss and deterioration of synapse plasticity in the hippocampus of APP/PS1 mice, while enhance synaptic plasticity in the control mice (158, 175)

Other combinations have reached as much as 20 percent on higher doses

Novel angiogenesis role of GLP-1(3236) to rescue diabetic ischemic lower limbs via GLP-1R-dependent glycolysis in mice

Recent Developments: 2025: Eli Lilly received FDA approval for tirzepatide (Zepbound) as a treatment for moderate-to-severe obstructive sleep apnea in adults with obesity the first pharmacotherapy approved for this indication expanding tirzepatide's approved uses beyond metabolic conditions into a respiratory indication affecting over 30 million Americans and supported by SURMOUNT-OSA trial data showing 63% reduction in apnea-hypopnea index

2 Data show that more than 50% of patients started on monotherapy will require a second medication to control diabetes after three years